Sudarshan Pharma Industries Ltd
Fundamental Score
Sudarshan Pharma Industries Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SUDARSHAN across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (15.51%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Revenue Growth (31.33%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (27.83% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (41.08% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (69.73% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Balanced Promoter Holding (57.39%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
8 factors identified
Margin Pressure Concerns (4.84%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Profit Decline Concern (-38.07%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Elevated Debt Levels (D/E: 1.56)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Weak Interest Coverage (2.23x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-12.20 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High Debt-to-Equity Ratio
Observation: Elevated financial risk due to high leverage.
Analysis: High debt levels may strain cash flows and increase financial risk during economic downturns.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Financial Statements
Comprehensive financial data for Sudarshan Pharma Industries Ltd
About SUDARSHAN
Business Overview
Sudarshan Pharma Industries Limited manufactures and sells specialty chemicals and intermediates for pharma, agro chemicals, coating, and various other industries in India. The company also focuses on manufactures active pharmaceuticals ingredients and vitamins manufacturing. In addition, it offers fine chemicals, solvents, agro chemicals, finish lubricants, inks, food colors, leather chemicals, oil field chemicals, lubricant specialties, paints and coatings, paper chemicals, personal and community hygiene products, pigments, polymers and additives, press room chemicals, sugar chemicals, textile chemicals, water treatment chemicals, rust preventives, metalworking fluids, PU additives, and other specialty chemicals. Further, the company provides antibiotics, antifungal, anthelmintic medications, antihypertensive, analgesics, anti-diabetic drugs, neurotonics, antihistamines, and cough syrups, as well as manufactures and supplies chemicals and solvents. Additionally, it engages in the contract manufacturing and outsourcing and supply of generic pharma formulation and medicines to healthcare institution, government, NGO, and hospitals. The company also exports its products to the United Kingdom, Australia, Uzbekistan, Syria, Oman, Taiwan, the Middle East, and North Africa regions. Sudarshan Pharma Industries Limited was incorporated in 2008 and is headquartered in Mumbai, India.
Company Details
Key Leadership
Corporate Events
Latest News
SUDARSHAN Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
As of 09 Feb 2026, 06:02 am IST, Sudarshan Pharma Industries Ltd (SUDARSHAN) is currently trading at ₹25.95. The stock has a market capitalization of ₹634.86 (Cr).
Is SUDARSHAN share price Overvalued or Undervalued?
SUDARSHAN is currently trading at a P/E ratio of 32.14x, compared to the industry average of 29.20x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Sudarshan Pharma Industries Ltd share price?
Key factors influencing SUDARSHAN's price include its quarterly earnings growth (Sales Growth: 31.33%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sudarshan Pharma Industries Ltd a good stock for long-term investment?
Sudarshan Pharma Industries Ltd shows a 5-year Profit Growth of 69.73% and an ROE of 14.83%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.56 before investing.
How does Sudarshan Pharma Industries Ltd compare with its industry peers?
Sudarshan Pharma Industries Ltd competes with major peers in the Specialty Chemicals. Investors should compare SUDARSHAN's P/E of 32.14x and ROE of 14.83% against the industry averages to determine its competitive standing.
What is the P/E ratio of SUDARSHAN and what does it mean?
SUDARSHAN has a P/E ratio of 32.14x compared to the industry average of 29.20x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹32 for every ₹1 of annual earnings.
How is SUDARSHAN performing according to Bull Run's analysis?
SUDARSHAN has a Bull Run fundamental score of 51.4/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SUDARSHAN belong to?
SUDARSHAN operates in the Specialty Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sudarshan Pharma Industries Ltd.
What is Return on Equity (ROE) and why is it important for SUDARSHAN?
SUDARSHAN has an ROE of 14.83%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Sudarshan Pharma Industries Ltd generates profits from shareholders' equity.
How is SUDARSHAN's debt-to-equity ratio and what does it indicate?
SUDARSHAN has a debt-to-equity ratio of 1.56, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.
What is SUDARSHAN's dividend yield and is it a good dividend stock?
SUDARSHAN offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has SUDARSHAN grown over the past 5 years?
SUDARSHAN has achieved 5-year growth rates of: Sales Growth 27.83%, Profit Growth 69.73%, and EPS Growth 41.08%.
What is the promoter holding in SUDARSHAN and why does it matter?
Promoters hold 57.39% of SUDARSHAN shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SUDARSHAN's market capitalization category?
SUDARSHAN has a market capitalization of ₹635 crores, placing it in the Small-cap category.
How volatile is SUDARSHAN stock?
SUDARSHAN has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SUDARSHAN?
SUDARSHAN has a 52-week high of ₹N/A and low of ₹N/A.
What is SUDARSHAN's operating profit margin trend?
SUDARSHAN has a 5-year average Operating Profit Margin (OPM) of 4.84%, indicating the company's operational efficiency.
How is SUDARSHAN's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 31.33% and YoY Profit Growth of -38.07%.
What is the institutional holding pattern in SUDARSHAN?
SUDARSHAN has FII holding of 20.79% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.